MethylGene Inc - Product Pipeline Review - 2012

Global Markets Direct, August 2012, Pages: 80

MethylGene Inc – Product Pipeline Review – 2012

Summary

Global Markets Direct’s pharmaceuticals report, “MethylGene Inc - Product Pipeline Review - 2012” provides data on the MethylGene Inc’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, MethylGene Inc’s corporate website, SEC filings, investor presentations and featured press releases, both from MethylGene Inc and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- MethylGene Inc - Brief MethylGene Inc overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of MethylGene Inc human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of MethylGene Inc with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the MethylGene Inc’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate MethylGene Inc’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of MethylGene Inc in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the MethylGene Inc’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with MethylGene Inc.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of MethylGene Inc and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of MethylGene Inc; MethylGene Inc - Key Therapeutics; MethylGene Inc - Pipeline Overview and Promising Molecules; MethylGene Inc - News; MethylGene Inc - Latest Updates; MethylGene Inc - Pipeline; MethylGene Inc - Discontinued/Dormant Projects

2
List of Tables 5
List of Figures 5
MethylGene Inc Snapshot 6
MethylGene Inc Overview 6
Key Information 6
Key Facts 6
MethylGene Inc – Research and Development Overview 7
Key Therapeutic Areas 7
MethylGene Inc – Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products – Monotherapy 11
Pipeline Products – Combination Treatment Modalities 12
MethylGene Inc – Pipeline Products Glance 13
MethylGene Inc Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
MethylGene Inc – Early Stage Pipeline Products 15
Pre-Clinical Products/Combination Treatment Modalities 15
MethylGene Inc – Drug Profiles 16
Kinase Inhibitors Program 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
MG-516 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
MG-96077 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
MGCD-265 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
MGCD-265 + Docetaxel 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
MGCD-265 + Erlotinib 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
MGCD-290 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
MGCD-290 + Fluconazole 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
mocetinostat 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Sirtuin Inhibitor Program 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
MethylGene Inc – Pipeline Analysis 31
MethylGene Inc – Pipeline Products by Therapeutic Class 31
MethylGene Inc – Pipeline Products By Target 32
MethylGene Inc – Pipeline Products by Route of Administration 33
MethylGene Inc – Pipeline Products By Mechanism of Action 34
MethylGene Inc – Recent Pipeline Updates 36
MethylGene Inc - Dormant Projects 41
MethylGene Inc - Discontinued Pipeline Products 42
Discontinued Pipeline Product Profiles 42
MG98 42
MG98 + Interferon 42
MethylGene Inc – Company Statement 43
MethylGene Inc – Locations And Subsidiaries 44
Head Office 44
MethylGene Inc, Recent Developments 45
MethylGene Inc- Press Release 45
Aug 02, 2012: MethylGene Provides Update On MGCD265 Clinical Development 45
Aug 02, 2012: MethylGene Recruits Patiens In Phase II trial Of MGCD290 45
May 29, 2012: MethylGene To Present Phase I Data Of MGCD265 At ASCO Annual Meeting 46
Apr 02, 2012: MethylGene Presents Preclinical Data For MGCD265 At American Association For Cancer Research Annual Meeting 46
Mar 28, 2012: MethylGene To Present Preclinical Data Of MGCD265 At AACR Annual Meeting 47
Sep 21, 2009: MethylGene To Resume Development Of Its HDAC Inhibitor, MGCD0103 (Mocetinostat) 48
Sep 15, 2009: MethylGene Presents Phase I Data For Its Novel Antifungal Agent, MGCD290, At The 49th Annual ICAAC Meeting 49
Sep 14, 2009: MethylGene Presents Preclinical Data For Its Beta-Lactamase Inhibitor, MG96077 49
Sep 02, 2009: MethylGene Initiates Phase II Program For MGCD265 In Solid Tumors And Non-Small Cell Lung Cancer Patients 50
May 28, 2009: MethylGene Reports Favorable Preliminary Phase I Data For MGCD265, Its Multi-Targeted (c-Met) Kinase Inhibitor. 51
Apr 21, 2009: MethylGene Presents Preclinical Data For Its Second Generation Oral Kinase Inhibitor, MG516 51
Financial Deals Landscape 53
MethylGene Inc, Deals Summary 53
MethylGene Inc, Pharmaceuticals & Healthcare, Deal Details 55
Partnerships 55
MethylGene Extends Its Research Collaboration With Otsuka Pharma 55
MethylGene Enters Into Royalty Stream And Milestone Arrangement With Celgene 57
Methylgene Enters Into Research Agreement With Pharmion 58
MethylGene And EnVivo Enter Into A Co-Development Agreement With CHDI 59
Licensing Agreements 61
Otsuka Pharma Extends Its Licensing Agreement With MethylGene 61
Methylgene Enters Into Collaboration And Licensing Agreement With Otsuka 62
MethylGene Enters Into License And Collaboration Agreement With Pharmion 63
Equity Offering 65
MethylGene Completes Private Placement Of $35.15 Million 65
MethylGene Announces Private Placement Of $15 Million 69
MethylGene Completes Private Placement Of $9.1 Million 70
MethylGene Completes Bought Deal Offering Of $17 Million 72
MethylGene Completes Private Placement Of $19 Million 74
Debt Offering 77
MethylGene Completes Private Placement Of Senior Unsecured Debentures For $0.39 Million 77
Appendix 79
Methodology 79
Coverage 79
Secondary Research 79
Primary Research 79
Expert Panel Validation 79
Contact Us 80
Disclaimer 80

List of Tables
MethylGene Inc, Key Information 6
MethylGene Inc, Key Facts 6
MethylGene Inc – Pipeline by Indication, 2012 8
MethylGene Inc – Pipeline by Stage of Development, 2012 10
MethylGene Inc – Monotherapy Products in Pipeline, 2012 11
MethylGene Inc – Combination Treatment Modalities in Pipeline, 2012 12
MethylGene Inc – Phase II, 2012 13
MethylGene Inc – Phase I, 2012 14
MethylGene Inc – Pre-Clinical, 2012 15
MethylGene Inc – Pipeline By Therapeutic Class, 2012 31
MethylGene Inc - Pipeline By Target, 2012 32
MethylGene Inc – Pipeline By Route of Administration, 2012 33
MethylGene Inc – Pipeline Products By Mechanism of Action, 2012 35
MethylGene Inc – Recent Pipeline Updates, 2012 36
MethylGene Inc - Dormant Developmental Projects,2012 41
MethylGene Inc - Discontinued Pipeline Products, 2012 42
MethylGene Inc, Deals Summary 53
MethylGene Extends Its Research Collaboration With Otsuka Pharma 55
MethylGene Enters Into Royalty Stream And Milestone Arrangement With Celgene 57
Methylgene Enters Into Research Agreement With Pharmion 58
MethylGene And EnVivo Enter Into A Co-Development Agreement With CHDI 59
Otsuka Pharma Extends Its Licensing Agreement With MethylGene 61
Methylgene Enters Into Collaboration And Licensing Agreement With Otsuka 62
MethylGene Enters Into License And Collaboration Agreement With Pharmion 63
MethylGene Completes Private Placement Of $35.15 Million 65
MethylGene Announces Private Placement Of $15 Million 69
MethylGene Completes Private Placement Of $9.1 Million 70
MethylGene Completes Bought Deal Offering Of $17 Million 72
MethylGene Completes Private Placement Of $19 Million 74
MethylGene Completes Private Placement Of Senior Unsecured Debentures For $0.39 Million 77

List of Figures
MethylGene Inc – Pipeline by Indication, 2012 8
MethylGene Inc – Pipeline by Stage of Development, 2012 10
MethylGene Inc – Monotherapy Products in Pipeline, 2012 11
MethylGene Inc – Combination Treatment Modalities in Pipeline, 2012 12
MethylGene Inc – Pipeline By Therapeutic Class, 2012 31
MethylGene Inc - Pipeline Products By Mechanism of Action, 2012 34

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Scientific Games Corporation - Company Analysis
• eBay - Strong Execution
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Amazon - Point of Realization in 2013?
• SunGard - Profile - US
• Ixia - Company Analysis
• Analysis of Google Inc
• Insight into Samsung Electronics' Notebook PC Business Model